INACTIVE INGREDIENT GUIDE



DIVISION OF
DRUG INFORMATION RESOURCES

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT

JANUARY 1996

— OFFICIAL USE ONLY —

INACTIVE INGREDIENT GUIDE

Purpose The *Inactive Ingredient Guide* contains all inactive ingredients present in approved drug products or conditionally approved drug products currently marketed for human use. The *Guide* is compiled by the Division of Drug Information Resources (DDIR). It provides CDER/CBER Reviewers with information on inactive ingredients in products which have been approved by the Agency. Once an inactive ingredient appears in a currently approved drug product for a particular route of administration, the inactive ingredient would not usually be considered new and may require a less extensive review.

Design The *Inactive Ingredient Guide* has been sorted first alphabetically by ingredient, and then by route of administration and dosage form. Routes of administration and dosage forms are derived from current approved labeling.

Definitions 21 CFR 210.3(b)(8,7, respectively) defines inactive ingredients and active ingredients as follows: "Inactive ingredient means any component other than the active ingredient. Active ingredient means any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man or animals. The term (active ingredient) includes those components that may undergo chemical change in the manufacture of the drug product and be present in the finished drug product in a modified form intended to furnish the specified activity or effect." As an exception of the CFR definition, inactive ingredients listed in the *Guide* include only those which are present in the final dosage form of the drug product.

Synonyms DDIR maintains a dictionary of all ingredients contained in submissions to CDER. Since many ingredients have synonyms (which do not appear in the *Inactive Ingredient Guide*), it may assist you to contact your Drug Information Officer if you cannot find a particular inactive ingredient.

Proprietary Inactive Ingredients DDIR does not always include the components of proprietary inactive ingredients (e.g., OPACODES). In such situations where components of proprietary inactive ingredients are included, you may have to search for such data under individual component entries.

Warnings The *Inactive Ingredient Guide* lists inactive ingredients specifically intended as such by the manufacturer. Some of these inactive ingredients could also be considered as active ingredients under different circumstances (see 21 CFR 210.3(b)(7,3)). Furthermore, reactants in radiopharmaceutical kits, or inactive ingredients which physically or chemically combine with active ingredients to facilitate drug transport are considered as inactive ingredients for the purposes of this *Guide*.

[Continued]

Contaminants The *Inactive Ingredient Guide* does not represent contaminants found in approved drug products.

Carcinogens and Teratogens If any of the inactive ingredients represented in the *Inactive Ingredient Guide* are proven to be carcinogenic, teratogenic, or embryotoxic, please notify DDIR immediately. DDIR will attempt to relay your concern to each medical officer and pharmacologist reviewer responsible for oversight of other approved drug products which contain the specified inactive ingredient.

CAS Number Many inactive ingredients have Chemical Abstracts Service (CAS) numbers associated with them. These can be found in the column to the right of the inactive ingredient. CAS numbers may be helpful to CDER/CBER Reviewers when initiating computer-assisted searches with the National Library of Medicine's online data bases.

Qualitative NDA Data The next five columns to the right of the CAS number serve to qualify the data presented. The 'NDA CT' reflects the total number of NDAs in which a particular inactive ingredient currently appears. The 'Last NDA' specifies which NDA was the most recent one to be approved by the Agency with this inactive ingredient. The 'APPROVAL DATE' and 'DIV' specify the approval date and Review Division responsible for evaluating this most recent NDA. The 'POTENCY RANGE' specifies the minimum and maximum amounts of inactive ingredients for each route of administration and dosage form. In some cases, values in the 'POTENCY RANGE' column have been collapsed into percentage of the total product in order to integrate data.

Colors The Certification Branch of the Division of Color Technology has designated permanently listed, provisionally listed, and delisted color additives. These appear in the Appendix. Please consult the 21 CFR 74 and 82 for detailed information on uses, restrictions, and tolerances of color additives.

Inactive Ingredient Structures Chemical structures of all inactive ingredients which have been submitted to the Agency are available for review by contacting Rona Sun or Kyung Kim, DDIR Chemists, at 443-3910.

Procedure for Obtaining Further Assistance The Division of Drug Information Resources can also provide you with more specialized searches on the automated data base from which the *Inactive Ingredient Guide* is generated. For assistance in using the *Guide*, to schedule a presentation on the *Guide*, or for a more detailed search, contact your DDIR Drug Information Officer on the following page or Mark Askine at 443-0500.

DIVISION OF DRUG INFORMATION RESOURCES
DRUG INFORMATION OFFICERS

Division of Cardio-Renal Drug Products, HFD-110	Diane Centeno-Deshields, R.Ph.
Division of Neuropharmacological Drug Products, HFD-120	Diane Centeno-Deshields, R.Ph.
Division of Oncologic Drug Products, HFD-150	Sharon Brownewell
Division of Medical Imaging, Surgical, and Dental Products, HFD-160	Herbert Thornton, R.Ph.
Division of Anesthesic, Critical Care, and Addiction Drug Products, HFD-170	Mary Guilderson
Division of Gastrointestinal and Coagulation Drug Products, HFD-180	Richard Lipov, R.Ph
Division of Metabolism and Endocrine Drug Products, HFD-510	Ronald Brown, R.Ph.
Division of Anti-Infective Drug Products, HFD-520	Mark W. Askine, R.Ph.
Division of Antiviral Drug Products, HFD-530	Lee Anne Parsons
Division of Dermatologic and Ophthalmologic Drug Products, HFD-540	Mark W. Askine, R.Ph
Division of Anti-Inflammatory, Analgesic, and Dental Drug Products, HFD-550	Mary Guilderson
Division of Pulmonary Drug Products, HFD-570	Sharon Brownewell
Division of Generic Drugs, HFD-600	Janet Anderson, R.Ph.

All DDIR Drug Information Officers can be contacted at 443-0500 and are located in Room 218 of the Chapman Building.

INACTIVE INGREDIENT FIELD DESCRIPTION

INGREDIENT ROUTE/DOSAGE FORM	CAS#
ACACIA BUCCAL/SUBLINGUAL; TABLET ORAL; CAPSULE ORAL; CAPSULE, SUSTAINED ACTION ORAL; POWDER	009000015

Ingredient Chemical substance added to enhance formulation of given dosage forms. Component of product other than active ingredient.

Route/Dosage Form Formulation intended for the specified route of administration or site of application.

CAS# Registry number assigned to a compound by Chemical Abstracts Service on a random basis.

NDA COUNT	LAST NDA	APPROVAL DATE	DIVISION	POTENCY RANGE
2	N85125	02/02/77	600	4.0 - 9.1 MG
1	N85296	04/01/77	600	
1	N17078	08/02/76	120	0.01 - 0.7 MG
1	N16640	08/03/73	510	21.0%

NDA Count Reflects total number of approved NDAs in which a particular inactive ingredient currently appears.

Last NDA Specifies which NDA was the most recent one to be approved by the Agency with this active ingredient.

Approval Date and DIV Specifies the approval date and the Review Division responsible for evaluating this most recent NDA.

Potency Range Specifies the minimum and maximum amounts of inactive ingredients for each route/dosage form.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.